Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

2017 ◽  
Vol 37 (4) ◽  
pp. 434 ◽  
Keyword(s):  
Clinical Trial ◽  
Bipolar Disorder ◽  
Adjuvant Treatment ◽  
Controlled Clinical Trial ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Obsessive Compulsive Symptoms ◽  
Double Blind Placebo

Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

2009 ◽  
Vol 21 (6) ◽  
pp. 285-291 ◽  
Author(s):  
Michelle Bernardo ◽  
Seetal Dodd ◽  
Clarissa S. Gama ◽  
David L Copolov ◽  
Olivia Dean ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bipolar Disorder ◽  
Substance Use ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Other Substances

Objective:To evaluate the effect of N-acetylcysteine (NAC) on substance use in a double-blind, placebo-controlled trial of NAC in bipolar disorder. It is hypothesised that NAC will be superior to placebo for reducing scores on the Clinical Global Impressions scale for Substance Use (CGI-SU).Methods:Participants were randomised to a 6-months of treatment with 2 g/day NAC (n = 38) or placebo (n = 37). Substance use was assessed at baseline using a Habits instrument. Change in substance use was assessed at regular study visits using the CGI-SU.Results:Among the 75 participants 78.7% drank alcohol (any frequency), 45.3% smoked tobacco and 92% consumed caffeine. Other substances were used by fewer than six participants. Caffeine use was significantly lower for NAC-treated participants compared to placebo at week 2 of treatment but not at other study visits.Conclusions:NAC appeared to have little effect on the participants who were using substances. A larger study on a substance-using population will be necessary to determine if NAC may be a useful treatment for substance use.

Pregabalin augmentation for resistant obsessive–compulsive disorder: a double-blind placebo-controlled clinical trial

CNS Spectrums ◽  
2019 ◽  
Vol 25 (4) ◽  
pp. 552-556
Author(s):  
Arash Mowla ◽  
Mehrnoosh Ghaedsharaf
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Obsessive Compulsive Disorder ◽  
Controlled Clinical Trial ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Good Tolerability ◽  
Double Blind Placebo ◽  
Compulsive Disorder ◽  
Current Medication

AbstractBackground and objective.Glutamate dysfunction has been shown to be associated with pathophysiology of obsessive–compulsive disorder (OCD). Our objective is to survey the effects of pregabalin (a glutamate-modulating agent) as an augmenting treatment for resistant OCD.Patients and methods.In this 12-week double-blind placebo-controlled clinical trial, 56 patients with resistant OCD were randomly allocated to receive either pregabalin or placebo plus their current medication (sertraline). Yale–Brown Obsessive Compulsive Scale (Y-BOCS) was used to evaluate the outcomes. Adverse effects were also registered.Results.Of the 56 patients with resistant OCD who were randomly allocated in 2 groups of pregabalin (n = 28) and placebo group (n = 28), 42 patients (22 in pregabalin group and 20 in placebo group) completed the trial. Throughout the trial, the mean score decreased from 26.13± 7.03 to 8.81 ± 3.47 in the pregabalin group (p < 0) and from 26.85 ± 4.34 to 17.63 ± 4.22 in the placebo group (p < 0). At the end of trial, 16 (57.14%) patients in the pregabalin group and 2 (7.14%) patients in the placebo group showed more than 35% decline in YBOCS (p < .01). The pregabalin group showed good tolerability and safety.Conclusions.Our study revealed that pregabalin, as an augmenting medication, is more effective than placebo in the treatment of patients with resistant OCD.

scholarly journals Oral Zinc Sulfate as Adjuvant Treatment in Children With Nephrolithiasis: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial

2015 ◽  
Vol 25 (6) ◽  
Author(s):  
Parsa Yousefichaijan ◽  
Ali Cyrus ◽  
Fatemeh Dorreh ◽  
Mohammad Rafeie ◽  
Mojtaba Sharafkhah ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adjuvant Treatment ◽  
Zinc Sulfate ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial

2009 ◽  
Vol 21 (5) ◽  
pp. 239-245 ◽  
Author(s):  
Michelle Bernardo ◽  
Seetal Dodd ◽  
Clarissa S. Gama ◽  
David L Copolov ◽  
Olivia Dean ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bipolar Disorder ◽  
Substance Use ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Other Substances

Objective:To evaluate the effect of N-acetylcysteine (NAC) on substance use in a double-blind, placebo-controlled trial of NAC in bipolar disorder. It is hypothesised that NAC will be superior to placebo for reducing scores on the Clinical Global Impressions scale for Substance Use (CGI-SU).Methods:Participants were randomised to 6-months of treatment with 2 g/day NAC (n = 38) or placebo (n = 37). Substance use was assessed at baseline using the Habits instrument. Change in substance use was assessed at regular study visits using the CGI-SU.Results:Amongst the 75 participants 78.7% drank alcohol (any frequency), 45.3% smoked tobacco and 92% consumer caffeine. Other substances were used by fewer than six participants. Caffeine use was significantly lower for NAC-treated participants compared with placebo at week 2 of treatment but not at other study visits.Conclusion:NAC appeared to have little effect on substance use in this population. A larger study on a substance using population will be necessary to determine if NAC may be a useful treatment for substance use.

Sign in / Sign up

Export Citation Format

Share Document